This protocol was submitted by the author(s) of the original paper via Bio-protocol's "Request a Protocol" feature.
Original Research Paper Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy
DOI: 10.1126/scitranslmed.aba2325
Science Translational Medicine , Jun 23, 2020
Related protocols in the same article
Ex vivo tissue cytokine analysis
Original Research Paper
Last updated date: Jun 26, 2020 View: 340


How to cite: Readers should cite both the Bio-protocol article and the original research article where this protocol was used:
1. Waite, J. C.(2020). Ex vivo tissue cytokine analysis. Bio-protocol. bio-protocol.org/prep346.
2. Waite, J., Wang, B., Haber, L., Hermann, A., Ullman, E., Ye, X., Dudgeon, D., Slim, R., Ajithdoss, D., Godin, S., Ramos, I., Wu, Q., Oswald, E., Poon, P., Golubov, J., Grote, D., Stella, J., Pawashe, A., Finney, J., Herlihy, E., Ahmed, H., Kamat, V., Dorvilliers, A., Navarro, E., Xiao, J., Kim, J., Yang, S., Warsaw, J., Lett, C., Canova, L., Schulenburg, T., Foster, R., Krueger, P., Garnova, E., Rafique, A., Babb, R., Chen, G., Oristian, N., Siao, C., Daly, C., Gurer, C., Martin, J., Macdonald, L., MacDonald, D., Poueymirou, W., Smith, E., Lowy, I., Thurston, G., Olson, W., Lin, J., Sleeman, M., Yancopoulos, G., Murphy, A. and Skokos, D.(2020). Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy . Science Translational Medicine 12(549). DOI: 10.1126/scitranslmed.aba2325
Copyright: Content may be subjected to copyright.
 Q&A
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.